MaxCyte (MXCT)
(Delayed Data from NSDQ)
$3.81 USD
-0.09 (-2.31%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $3.80 -0.01 (-0.26%) 7:10 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.81 USD
-0.09 (-2.31%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $3.80 -0.01 (-0.26%) 7:10 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Zacks News
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
MaxCyte (MXCT) delivered earnings and revenue surprises of 35.71% and 27.18%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Vir Biotechnology (VIR) delivered earnings and revenue surprises of -9.68% and 71.79%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
MaxCyte (MXCT) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
MaxCyte (MXCT) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Does MaxCyte (MXCT) Have the Potential to Rally 85% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 85% in MaxCyte (MXCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Recent Price Trend in MaxCyte (MXCT) is Your Friend, Here's Why
by Zacks Equity Research
MaxCyte (MXCT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
MaxCyte (MXCT) delivered earnings and revenue surprises of 35.71% and 46.35%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Qiagen (QGEN) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 2% and 0.22%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
MaxCyte, Inc. (MXCT) delivered earnings and revenue surprises of 0% and 1.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
UniQure (QURE) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
uniQure (QURE) delivered earnings and revenue surprises of -59.80% and 79.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of 8.97% and 43.96%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
MaxCyte, Inc. (MXCT) Loses 18.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
MaxCyte, Inc. (MXCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
MaxCyte, Inc. (MXCT) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
MaxCyte, Inc. (MXCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
MaxCyte, Inc. (MXCT) delivered earnings and revenue surprises of 33.33% and 2.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Vanda Pharmaceuticals (VNDA) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Vanda (VNDA) delivered earnings and revenue surprises of -40% and 8%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
MaxCyte, Inc. (MXCT) Moves 9.3% Higher: Will This Strength Last?
by Zacks Equity Research
MaxCyte, Inc. (MXCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
MaxCyte, Inc. (MXCT) delivered earnings and revenue surprises of 0% and 6.76%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 55.43% and 714.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Akoya Biosciences (AKYA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akoya (AKYA) delivered earnings and revenue surprises of -38.24% and 5.69%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?